This page shows the latest Ubrelvy news and features for those working in and with pharma, biotech and healthcare.
The new drug’s approval by the FDA follows the agency’s green light for Allergan’s Ubrelvy (ubrogepant) in December. ... That is slightly lower than the $4, 896 annual list price for Ubrelvy, according to ICER.
The product category has extended with an orally-active CGRP drug in December when Allergan secured FDA approval for Ubrelvy (ubrogepant), though this isn’t a direct competitor as it is
Allergan chief executive Brent Saunders said Allergan is entering 2020 with “strong momentum”, helped by approvals such as an FDA green light for new acute migraine therapy Ubrelvy (ubrogepant).
Its closest competitor is Allergan’s Ubrelvy (ubrogepant) – an oral CGRP inhibitor which also has FDA approval in the treatment of acute migraine, with or without aura.
The US regulator has given a green light to Ubrelvy (ubrogepant) for acute migraine with or without aura, and Ireland-domiciled Allergan says it intends to launch the drug in the ... Atogepant is expected to account for the bulk of Allergan’s sales
New data keeps Allergan ahead of rival Biohaven
More from news
Approximately 1 fully matching, plus 5 partially matching documents found.
To succeed in the acute treatment setting, rimegepant will also have to beat competitors like Reyvow and Ubrelvy, both of which are also oral drugs with very attractive profiles. ... Allergan’s Ubrelvy is the only other oral CGRP antagonist approved
More from intelligence
Approximately 0 fully matching, plus 1 partially matching documents found.
WE’RE ON A MISSION
To enhance patients’ lives through communication that changes behaviour and improves patient health outcomes....